Pittman S, Catovsky D
Br J Haematol. 1984 Dec;58(4):649-60. doi: 10.1111/j.1365-2141.1984.tb06112.x.
Lymphocytes from 33 out of 63 patients with B-cell chronic lymphocytic leukaemia (B-CLL) were successfully stimulated for cytogenetic analysis by means of two B-cell mitogens: pokeweed mitogen and lipopolysaccharide-B, used after pretreatment of the cells with neuraminidase and galactose oxidase. All patients had abnormal clones in 30-100% of the cells analysed. Chromosomes more frequently involved were Nos. 1, 3, 6, 11, 12, 13 and 14. The most common abnormality was a marker 14q+ (breakpoint 14q32) seen in 17 cases; trisomy 12 was observed in seven cases. A clinical scoring system was used to investigate the correlation of chromosome abnormalities with prognosis. The group with 14q+ was often associated with features of progressive disease, namely; prolymphocytoid or Richter transformation, refractoriness to therapy, high WBC and advanced staging. A significant difference in survival was observed between patients with 14q+ and the rest: median survival from diagnosis being 45 months and over 64 months, respectively (P less than 0.05); when survival was calculated from the time of chromosome analysis the values were 8 months and more than 41 months, respectively (P less than 0.01). It is suggested that 14q+ is acquired during the evolution of CLL and that this development may be a key event in the clinical progression of B-CLL. Other abnormalities, including trisomy 12, were not found to be associated with a worse prognosis.
63例B细胞慢性淋巴细胞白血病(B-CLL)患者中,33例患者的淋巴细胞通过两种B细胞促有丝分裂原成功刺激用于细胞遗传学分析:商陆促有丝分裂原和脂多糖-B,在细胞用神经氨酸酶和半乳糖氧化酶预处理后使用。所有患者在分析的30%-100%的细胞中都有异常克隆。更常涉及的染色体是1、3、6、11、12、13和14号染色体。最常见的异常是14q+标记(断点14q32),见于17例;7例观察到12号染色体三体。使用临床评分系统研究染色体异常与预后的相关性。14q+组常与疾病进展特征相关,即幼淋巴细胞样或Richter转化、对治疗耐药、白细胞计数高和分期 advanced。14q+患者与其余患者的生存率有显著差异:诊断后的中位生存期分别为45个月和64个月以上(P<0.05);从染色体分析时计算生存率时,数值分别为8个月和41个月以上(P<0.01)。提示14q+是在CLL演变过程中获得的,这种发展可能是B-CLL临床进展的关键事件。其他异常,包括12号染色体三体,未发现与预后不良相关。